Tafamidis, developed as a pharmacological chaperone, improved the prognosis of patients with ATTR cardiac amyloidosis by stabilizing the tetrameric structure of transthyretin and inhibiting its tissue deposition5,6. The gene discussed is TTR; the disease is cardiac amyloidosis.